Skip to main content

Table 2 Comparison of breast cancer studies from East Africa

From: Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

Study Country City Patients with Breast Cancer Retrospective or prospective study design Female Male Ethnic groups considered in study Immune cells quantified Median Mean ER+ ER- ER+ ER- PR+ PR- PR+ PR- HER2+ HER2- HER2+ HER2- TN TN Time Period of Sample Collection Date of Publication
(N)# (%) (%) age age (N) (N) (%) (%) (N) (N) (%) (%) (N) (N) (%) (%) (N) (%)
This Study, Sawe et al. Kenya Eldoret 48 (68)A Prospective 93 7 Yes CD68, CD163, CD4, CD8, CD20, CD25 48.5 51.9 29 20 59 41 19 29 40 60 7 42 14 86 16 33 2011–2013  
Nalwoga et al. Uganda Kampala 65B Retrospective 100 no B No None   49.8 23 42 35 65 15 50 23 77 19 46 29 71   34 G 1993–2002 2007
Roy et al. Uganda Kampala 35 (45)B,C Retrospective 96 4 C,B No None    27 18 60 40      5 39 11 89 16 36 2000–2004 2011
Bird et al. Kenya Kijabe 34 (129)D Prospective 97 3 No None 47 48 29   24       9 25 26 74 15 44 2001–2007 2008
Nyagol et al. Kenya Nairobi 158B Prospective 100 no B No None   47 59 99 37 63 77 81 49 51 44 114 28 72 44 28 2002–2004 2006
Wata et al. Kenya Nairobi 54 (219)B,E Retrospective 100 no B No WBC, platelets 45 46.5 30 34 47 53 28 36 44 56 19 35 35 65    2007–2008 2013
Kantelhardt et al. Ethiopia Addis Ababa 352B Retrospective 100 no B No None   40.1-43H 230 122 65 35 176 168 51 49 n.d. n.d. n.d. n.d.    2005–2010 2014
Burson et al. Tanzania Dar es Salaam 57 (488)I Retrospective 97 3 No None   49.4 33 32 51 49 29 36 45 55 n.d. n.d. n.d. n.d.    2009–2010 2010
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor, TN triple negative (ER-,PR-,HER2-), N number, % = percent, n.d not determined
  2. #The number before the parentheses is the number of patients used for analysis of receptor status and is summarized individually by the indicated superscripts
  3. The number in parentheses represents the total number of patients with breast cancer in the study.
  4. A N = 48 patients with PR and triple negative data. N = 49 with ER, HER2 data. Excluded patients who did not provide consent or who had chemotherapy prior to surgery
  5. BOnly females included in study
  6. C N = 35 patients with triple negative data. N = 44 patients with HER2 data. 2 of 47 (4 %) patients were male but were excluded from the study
  7. D N = 34 patients with HER2/triple negative data. 120 patients with hormone receptor data
  8. E N = 54 patients with HER2 data. N = 64 patients with ER data. N = 64 for PR. Excluded if <18 yrs old, male, or if chart did not have a date of diagnosis
  9. FNo hormonal receptor data in this study
  10. GDefined in this study by staining for Cytokeratin 5/6 and P-Cadherin as basal subtype markers, rather than ER, PR, and HER2
  11. HMean is 43 years old for ER+ and 40.1 years old for ER- patients
  12. I N = 57 patients with ER and PR data. No HER2 data for these patients